静脉铁剂在肾性贫血中的治疗作用

目的观察右旋糖酐铁静脉注射治疗尿毒症致肾性贫血的疗效和不良反应。方法80例尿毒症血液透析病人随机分为两组。对照组:速立菲200 mg,每日3次,口服。治疗组:右旋糖酐铁100 mg,每周1次,静脉滴注。两组均治疗10周,并同时应用促红细胞生成素(EPO)9 000U/周。结果对照组治疗后血红蛋白(Hb)、红细胞压积(Hct)较治疗前有明显升高(P<0.01),但转铁蛋白饱和度(TSAT)、铁蛋白(FT)与治疗前对比无明显提高(P>0.05)。治疗组治疗后Hb、Hct、TSAT、FT较治疗前均有显著升高(P<0.001)。两组治疗后的Hb、Hct、TSAT、FT对比,治疗组比对照组有显著升高(P<0.001)。结论静脉注射铁剂能有效补充EPO治疗中所需要的铁储备,疗效优于口服,不良反应少。

Effect of intravenous ferralia on renal anemic

Objective To investigate the curative effect and untoward effect of intravenous therapy with iron dextran for renal anemia induced by uremia. Methods Eighty patients of uremia for hemodialysis were divided into two groups randomly.Forty patients who took ferrous succinate tablets for 200 mg three times a day orally were regarded as the controls.The other forty patients who received intravenous therapy with iron dextran for 100 mg once a week were enrolled in this study as the treatment group.Both groups were treated as long as 10 weeks. Results In the controls,the hemoglobin (Hb) levels after the therapy were significantly higher than that before the thrapy(P<0.01).But the heamatocrit (Hct),transferrin saturation (TSAT),ferritin (FT) levels were not significantly higher than that before the therapy (P>0.05).In the treatment group,Hb,Hct,TSAT,FT after the therapy were all significantly higher than that before the therapy (P<0.001).In the treatment group,Hb,Hct,TSAT,FT after the therapy were significantly higher than that in the controls (P<(0.001)). Conclusion Intravenous therapy with ferralia can keep sufficient iron stores needed duning erythopoietin treatment. It is quiclily up to the standard for the treatment for anemia,and associated with skimp untoward effect.